Pfizer launches ‘Campaign Against Migraine’ website
pharmafile | June 18, 2012 | News story | Medical Communications | Botox, Pfizer, Relpax, digital, migraine
Pfizer has launched a new website called ‘Campaign Against Migraine’ to help migraine sufferers in the US learn more about their condition.
Campaign Against Migraine offers patients new tools to help them better understand the types of headaches they may experience. It also offers an interactive quiz to help them determine how well their current treatment is working.
Among the website’s other features is the ‘ID Migraine’ quiz, a migraine diary to help sufferers record their symptoms and migraine triggers, and a doctor discussion guide.
Pfizer is hoping this disease awareness campaign will help increase sales of its migraine treatment Relpax (eletriptan HBr), which is licensed to treat acute migraine.
The drug made $341 million last year, around half of which came from sales in the US. The firm currently competes for market space with GSK’s Imitrex, which made around $100 million less than Relpax last year.
But both companies will start coming under pressure from Allergan’s Botox, which recently gained a new license for migraines in the US and Europe.
Campaigns such as these are often used to boost sales of migraine drugs, and to shore up awareness of established medicines for the condition, ahead of a new drug coming onto the market.
According to the Migraine Research Foundation, more than 30 million Americans suffer from migraines.
But Pfizer says that migraine continues to be a poorly understood condition that is frequently undiagnosed and undertreated.
Pfizer points to a recent survey of more than 9,000 migraine sufferers, which shows that 8 out of 10 may not be on the right medication to treat their condition.
“With the availability of effective treatments today, the fact that so many sufferers are potentially not getting the relief they should is disturbing,” said Elodie Ramos, migraine portfolio medical lead for US brands.
“We’re giving patients information that can make a positive change in their lives.”
Pfizer has spent much time and money on digital disease awareness campaigns, such as its interactive online football game for ankylosing spondylitis and its more recent site for Dupuytren’s disease.
Ben Adams is the reporter for Pharmafocus and InPharm.com and manages the DigiBlog site. He can be contacted via: email or Twitter.
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
